Managing Director & Partner
Sven Fraterman is a core member of Boston Consulting Group's Health Care practice specializing in biopharma, and the lead partner for the firm's Center for Oncology Insights. He focuses on R&D, medical affairs, and commercial considerations, particularly in the areas of oncology, immunology, rare diseases, and cardio-renal metabolic diseases.
Sven works with large pharmaceutical and other health care companies, and small and mid-sized biotechs. Among other engagements, he has conducted several due diligences of clinical-stage assets, worked with several clients on optimizing their portfolio and individual R&D programs, developed launch and market entry strategies, and led several operating model redesigns on company and functional levels (including commercial and R&D functions).
Before joining the firm, Sven was BU Head of Hospital, Oncology and Biosimilars, at Sandoz Switzerland, Global Director Strategic Planning at Sandoz International, International Senior Product Manager Marketing Pipeline Products at Boehringer Ingelheim, Engagement Manager at another consulting company, and a visiting scientist at the University of Pennsylvania Medical School.
Gene therapy, stem cells, and other advances are changing the way complex diseases are treated. To capitalize, biopharma and biotech companies need to make strategic decisions about where to focus their efforts.
Once a visionary ambition, synthetic control arms are poised to take off. Now is the time for pharma companies to identify opportunities and gain experience.